Explore our sister journals here.

Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Accepted for/Published in: JMIRx Med

Date Submitted: Jan 14, 2025
Date Accepted: Jan 14, 2025

The final, peer-reviewed published version of this preprint can be found here:

Peer Review of “Safety and Efficacy of Chimeric Antigen Receptor T-Cell Therapy for Recurrent Glioblastoma: An Augmented Meta-Analysis of Phase 1 Clinical Trials (Preprint)”

Fairhurst V, Mahmoud RSG, Olatoye T, Sakilay S

Peer Review of “Safety and Efficacy of Chimeric Antigen Receptor T-Cell Therapy for Recurrent Glioblastoma: An Augmented Meta-Analysis of Phase 1 Clinical Trials (Preprint)”

JMIRx Med 2025;6:e71293

DOI: 10.2196/71293

PMCID: 11784631

Peer Review Report

  • Vanessa Fairhurst; 
  • Randa Salah Gomaa Mahmoud; 
  • Toba Olatoye; 
  • Sylvester Sakilay

ABSTRACT

This is a peer review report related to MS ID#68203


 Citation

Please cite as:

Fairhurst V, Mahmoud RSG, Olatoye T, Sakilay S

Peer Review of “Safety and Efficacy of Chimeric Antigen Receptor T-Cell Therapy for Recurrent Glioblastoma: An Augmented Meta-Analysis of Phase 1 Clinical Trials (Preprint)”

JMIRx Med 2025;6:e71293

DOI: 10.2196/71293

PMCID: 11784631

Per the author's request the PDF is not available.

© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.